CATEN CATEN CATEN EUROCARD EUROCARD ANGLOLOL ANGLOLOL NORTENALOL NORTENALOL CARDI CARDI CARDI CARICARD CARICARD ATLIN ATLIN ATLIN ATLIN PLUS BLOCKER BLOCKER NOMIN NOMIN CARDIOLITE CARDIOLITE CARDIOLITE ATENORM ATENORM PULSBIT-50 ETHINOLOL ETHINOLOL ADONAX ADONAX ADONAX ADONAX EPLACARD-100 EPLACARD-50 HYPERNOL HYPERNOL ATN ATN BLOKIUM-DIU BLOKIUM-DIU BLOKIUM BLOKIUM BLOKIUM KANTROL IQANOL IQANOL TENORET-50 TENORMIN TENORMIN TENORMIN SAFECARD SAFECARD ATENOLOL ATENOLOL DIOLIT DIOLIT DIOLIT NORMITAB PLUS NORMITAB NORMITAB NORMITAB QUNOTEN QUNOTEN QUNOTEN ATELOR ATELOR ATELOR MINOCARD MINOCARD HARTEN HARTEN HARTEN CONTROBEAT CONTROBEAT CONTROBEAT JEOTOL RETLOL RETLOL CARDAXEN CARDAXEN CARDAXEN PLINOL PLINOL ATENOLOL SYDLOL SYDLOL COXALOL COXALOL ANTOLOL ANTOLOL ATOMIN EOURMIN EOURMIN WILNORMIN WILNORMIN ZAFNOL ATENOLOL ALT PULSE PULSE CO-PULSE CO-PULSE CO-PULSE K-NOL-50 K-NOL PLUS K-NOL TOTAMOL TOTAMOL TOTAMOL CARTAC CARTAC CARTAC CARTAC ATRIL ATRIL MEDI-HEART MEDI-HEART HETOLOL EZILIFE EZILIFE EZILIFE TINOCARD-50 TINOCARD-100 ATENOLOL JINGLE JINGLE JINGLE ATENOSCOT ATENOSCOT ATENOSCOT CAREEB CAREEB BETAFIX BETAFIX TYNOTIN TYNOTIN CARDILOL CARDILOL ATENBLOCK ATENBLOCK KONDUCT KONDUCT ATROMIN ATROMIN ATL ATL CARDIPRO CARDIPRO CARDEXOL BEKOLOL BEKOLOL CARDAT CARDAT B-LOC B-LOC TROBEL TROBEL KVIK KVIK KVIK CARILIF ATENO-HEART ATENO-HEART TENIF TENIF MAKLOL ATENOCARD CARDIWIN CARDIWIN CARDIWIN ATECARD ATECARD SLECTIVE SLECTIVE ATENOPHARM ATENOPHARM ATENOPHARM WNSOL ATENOSAF ATENOSAF CARDIOLITE PLUS ROCARD ROCARD

Dose: 2.5 mg
Single Dose: 2.5 (2.5)
Frequency: As recommended.
Route: IV
Instructions: At a rate of 1 mg/min

Dose: 1 to 2 mg/kg
Single Dose: 1.5 (1.5)
Frequency: 24 hourly
Route: oral
Instructions: Gradually increase the dose

Dose: 1 to 2 mg/kg
Single Dose: 1.5 (1.5)
Frequency: 24 hourly
Route: Oral
Instructions: -

. It is of Synthetic origin and belongs to Phenylcetamide. It belongs to Beta-1 adrenergic antagonist pharmacological group on the basis of mechanism of action and also classified in Beta Blocker, Beta1 Selective pharmacological group.The Molecular Weight of Atenolol is 266.30. It is weakly alkaline drug and Its pKa is 9.6.

Atenolol is contraindicated in conditions like Asthma,Depression,Heart failure,Cardiogenic shock,Bronchitis,Second or third degree A-V block.

The severe or irreversible adverse effects of Atenolol, which give rise to further complications include Hypotension, Bronchospasm, Impotence, AV-block, Agranulocytosis, Hyperglycemia, Sinus bradycardia, Oculomucocutaneous syndrome.Atenolol produces potentially life-threatening effects which include Heart failure. which are responsible for the discontinuation of Atenolol therapy.The signs and symptoms that are produced after the acute overdosage of Atenolol include Bradycardia, Convulsions, Coma, Ventricular asystole.The symptomatic adverse reactions produced by Atenolol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Fatigue, Alopecia, Diarrhea, Dyspnea, Cold extremities, Constipation, Insomnia, Pruritus, Impotence, Depression, Blood dyscrasias, Exfoliative dermatitis, Paresthesias, Hyperpigmentation, Wheezing, Vivid dreams, Xerosis.

Atenolol is primarily indicated in conditions like Angina, Angina pectoris, Cardiac arrhythmia, Early intervention within 12 hrs of myocardial infarction, Hypertension, Myocardial infarction, To prevent recurrence of neural tube defect, and can also be given in adjunctive therapy as an alternative drug of choice in Alcohol withdrawal, Migraine prophylaxis.

Atenolol is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAdrenalineAtenolol may enhance the vasopressor effect of Adrenaline.Adrenaline used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.ModerateImmediateMonitor increased pressor effects of Adrenaline if used in patients receiving Atenolol. The amount of Adrenaline in dental procedures as part of local anesthetic administration is not likely to be of clinical concern. Infiltrating larger volumes of local anesthetics for other surgical procedures (eg, >0.06 mg Adrenaline) may cause clinically-relevant problems.AldesleukinEnhanced hypotensive effect when aldesleukin given with Beta-blockers (e.g atenolol).AlfuzosinEnhanced hypotensive effects when alpha-blockers (e.g Alfuzosin) given with beta-blockers (e.g Atenolol).MajorAmiodarone (HCl)Increased myocardial depression when beta-blockers (e.g Atenolol) given with antiarrhythmics (e.g Amiodarone).Amlodipine (Besylate)Enhanced hypotensive effects when calcium-channel blockers (e.g Amlodipine) given with beta-blockers (e.g Atenolol)Clonidine (HCl)Atenolol may enhance the rebound hypertensive effect of Clonidine (HCl).This effect can occur when the Clonidine Hcl is abruptly withdrawn.MajorRapidIf possible, withdraw Atenolol several days before slowly withdrawing. clonidine. Consider the use of labetalol in place of clonidine, as it has both alpha- and beta-blocking activity. Use a cardioselective beta-blocker (such should pose less risk than nonselective agents). Monitor closely for acute rise in blood pressure.DiazepamAtenolol may increase the serum concentration of Diazepam.MinorNo action required.DigoxinAtenolol may enhance the bradycardic effect of digoxin.ModerateMonitor bradycardia if these two agents are used concomitantly.Diltiazem (HCl)Diltiazem may enhance the hypotensive effect of Atenolol. Bradycardia and signs of heart failure have also been reported.Diltiazem may decrease the metabolism, via CYP isoenzymes, of Atenolol.ModerateThough usually safe and effective during concomitant use, monitor bradycardia, hypotension, or signs of heart failure during concomitant use of Atenolol and Diltiazem. phthalmic beta-blockers are of little concern.DisopyramideBoth drugs produce additive effect on heart results in reduced cardiac output, hypotension and bradycardia. Atenolol also decreases the clearence of disopyramide.Intravenous administration of these agents may exacerbate the risk of adverse effects.ModerateClosely monitor for cardiac output, blood pressure, heart rate and ECG.FlurbiprofenAntihypertensive effect of Atenolol may decrease if use with Flurbiprofen sodium.IndacaterolBeta-blockers may exacerbate bronchospasms in patients with COPD.monitor closelyIndomethacinIndomethacin alters the antihypertensive effects of atenolol by inhibiting synthesis of renal prostaglandins results in unopposed pressor activity producing hypertension.ModerateClosely monitor the patient for changed antihypertensive response whenever therapy with indomethacin starts, stopped or modified.LacidipineEnhanced hypotensive effects when beta-blockers (e.g Atenolol) given with calcium-channel blockers (e.g Lacidipine).Metformin (HCl)Atenolol enhance the hypoglycemic effect of metformin.ModerateMonitoring of patient blood glucose level should be done when these drugs are coadministered.NaphazolineConcurrent use may result in interaction. Dosage adjustment or special monitoring during concurrent use is necessary.NifedipineCombined use of atenolol with nifedipine decrease the rate, conduction and contractility of heart particularly in patients of ventricular or conduction abnormalities.by decreasing peripheral vascular resistance.ModerateDosage regimen should be adjusted accordingly. Closely monitor the hemodynamic effect and tolerance of patient.PrazosinEnhanced hypotensive effects when alpha-blockers (e.g Prazosin) given with beta-blockers (e.g Atenolol), also increased risk of first-dose hypotension. MajorThioridazine (HCl)Both agents act additively and produce hypotensive and central nervous system depressant effect.ModerateClosely monitor for hypotension and prolonged CNS depression. Patient should notify to physician about excessive side effects.Verapamil (HCl)Verapamil may enhance the hypotensive effect of Atenolol.Bradycardia and signs of heart failure have also been reported.Verapamil may decrease the metabolism, via CYP isoenzymes, of Atenolol.ModerateThough usually safe and effective during concomitant use, monitor bradycardia, hypotension, or signs of heart failure during concomitant use of Atenolol and Verapamil. Ophthalmic beta-blockers are of little concern. It is recommended that atenolol should not be administered IV within 24 hourrs of discontinuing Verapamil. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store at room temperature, Below 30°C or in refrigerator. Do not Freeze. Protect from Sunlight. Tab Store in a well closed container, Below 40°C. Protect from Sunlight and Moisture.

Atenolol should be used with caution in patients with poorly controlled diabetes mellitus particularly brittle diabetes, in patients with liver or kidney impairments, in hyperthyroidism or thyrotoxicosis because the drug can mask the tachycardia that occur in this condition. Abrupt withdrawal of atenolol in hyperthyroidism patient can precipitate a thyroid storm. Avoid abrupt withdrawal in angina patients. Use with caution during pregnancy.